Kiley Cook
Family · San Antonio, TXNPI 1083294433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 385 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- AbbVie$1K
- GSK$616
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$526
- Lilly USA, LLC$437
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,784100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $1,680 |
| AstraZeneca | 71 | $1,337 |
| AbbVie | 53 | $1,005 |
| GSK | 42 | $616 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $526 |
| Lilly USA, LLC | 25 | $437 |
| Pfizer | 28 | $406 |
| Abiomed | 3 | $277 |
| Shield Therapeutics Inc | 13 | $210 |
| Viiv Healthcare Company | 6 | $136 |
| Axsome Therapeutics, Inc. | 6 | $136 |
| Supernus Pharmaceuticals, Inc. | 7 | $109 |
| Dexcom, Inc. | 4 | $104 |
| Merck | 5 | $88 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Medtronic | 3 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Amgen | 3 | $46 |
| Exact Sciences | 2 | $46 |
| Tris Pharma Inc | 2 | $44 |
| Corcept Therapeutics | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Dynavax Technologies Corporation | 3 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $23 |
| Philips North America LLC | 1 | $21 |
| Organon | 1 | $20 |
| Kaleo, Inc. | 1 | $18 |
| Corium, LLC | 1 | $16 |
| Bayer | 1 | $15 |
| Novartis | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,784 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $60,977 |
| MounjaroTirzepatide | 31 | $31,023 |
| EliquisApixaban | 12 | $8,709 |
| Rosuvastatin Calcium | 80 | $996 |
| Atorvastatin Calcium | 93 | $764 |
| Fluticasone Propionate | 51 | $701 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $574 |
| Omeprazole | 35 | $545 |
| Gabapentin | 33 | $463 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 45 | $448 |
| Levothyroxine Sodium | 59 | $406 |
| Losartan Potassium | 30 | $374 |
| Metoprolol Succinate | 24 | $332 |
| Cefdinir | 14 | $296 |
| Metformin Hcl | 43 | $281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,680 | $60,97751 claims |
| Lilly USA, LLCMounjaro | $437 | $31,02331 claims |
| PfizerEliquis | $406 | $8,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.